Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,593 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association between the Co-administration of Histamine H2 Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis.
Yamazaki T, Uozumi R, Kawazoe H, Kitazume Y, Iihara H, Fujii H, Takahashi M, Arai T, Murachi Y, Sato Y, Mikami T, Hashiguchi K, Yoshizawa T, Takahashi K, Fujita Y, Hosokawa Y, Morozumi I, Tsuchiya M, Yokoyama A, Hashimoto H, Furukawa T. Yamazaki T, et al. J Cancer. 2022 Aug 8;13(10):3073-3083. doi: 10.7150/jca.73385. eCollection 2022. J Cancer. 2022. PMID: 36046656 Free PMC article.
Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study.
Kitazume Y, Kawazoe H, Uozumi R, Yoshizawa T, Iihara H, Fujii H, Takahashi M, Arai T, Murachi Y, Sato Y, Mikami T, Hashiguchi K, Yamazaki T, Takahashi K, Fujita Y, Hosokawa Y, Morozumi I, Tsuchiya M, Yokoyama A, Hashimoto H, Yamaguchi M. Kitazume Y, et al. Among authors: yamazaki t. Sci Rep. 2022 Apr 21;12(1):6561. doi: 10.1038/s41598-022-10008-2. Sci Rep. 2022. PMID: 35449143 Free PMC article.
Clinical and genomic features of non-small cell lung cancer occurring in families.
Miyabe S, Ito S, Sato I, Abe J, Tamai K, Mochizuki M, Fujimori H, Yamaguchi K, Shindo N, Shima H, Yamazaki T, Abue M, Okada Y, Yasuda J. Miyabe S, et al. Among authors: yamazaki t. Thorac Cancer. 2023 Apr;14(10):940-952. doi: 10.1111/1759-7714.14825. Epub 2023 Mar 3. Thorac Cancer. 2023. PMID: 36869602 Free PMC article.
Establishment of a monoclonal antibody against glycosylated CD271 specific for cancer cells in immunohistochemistry.
Fujii K, Morita S, Mochizuki M, Shibuya-Takahashi R, Fujimori H, Yamaguchi K, Abe J, Yamazaki T, Imai T, Sugamura K, Yasuda J, Satoh K, Sato I, Saito-Koyama R, Fujishima F, Sasano H, Kato Y, Matsuura K, Asada Y, Tamai K. Fujii K, et al. Among authors: yamazaki t. Cancer Sci. 2022 Aug;113(8):2878-2887. doi: 10.1111/cas.15340. Epub 2022 Apr 18. Cancer Sci. 2022. PMID: 35343032 Free PMC article.
Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study.
Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Sakurai D, Asakage T, Doi I, Yamada T, Homma A. Hanai N, et al. Among authors: yamazaki t. Int J Clin Oncol. 2021 Mar;26(3):494-506. doi: 10.1007/s10147-020-01829-0. Epub 2020 Nov 21. Int J Clin Oncol. 2021. PMID: 33219460 Free PMC article.
Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study.
Yasumatsu R, Shimizu Y, Hanai N, Kariya S, Yokota T, Fujii T, Tsukahara K, Ando M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Yonekura S, Asakage T, Nekado T, Yamada T, Homma A. Yasumatsu R, et al. Among authors: yamazaki t. Int J Clin Oncol. 2022 Jan;27(1):95-104. doi: 10.1007/s10147-021-02047-y. Epub 2021 Nov 13. Int J Clin Oncol. 2022. PMID: 34773525 Free PMC article.
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota T, Kiyota N, Kii T, Chin K, Zenda S, Kojima T, Bando H, Yamazaki T, Iwasa S, Honma Y, Hamauchi S, Tsushima T, Ohtsu A. Satake H, et al. Among authors: yamazaki t. Cancer Chemother Pharmacol. 2016 Jul;78(1):91-9. doi: 10.1007/s00280-016-3062-2. Epub 2016 May 18. Cancer Chemother Pharmacol. 2016. PMID: 27193097 Free PMC article. Clinical Trial.
3,593 results